Access the full text.
Sign up today, get DeepDyve free for 14 days.
Takanobu Kato, T. Matsumura, T. Heller, S. Saito, Ronda Sapp, K. Murthy, T. Wakita, T. Liang (2007)
Production of Infectious Hepatitis C Virus of Various Genotypes in Cell CulturesJournal of Virology, 81
N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, C. Sato (1996)
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.The New England journal of medicine, 334 2
David Thomas, C. Thio, Maureen Martin, Y. Qi, D. Ge, C. O’hUigin, J. Kidd, K. Kidd, S. Khakoo, G. Alexander, J. Goedert, G. Kirk, S. Donfield, H. Rosen, L. Tobler, M. Busch, J. McHutchison, D. Goldstein, M. Carrington (2009)
Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 461
V. Suppiah, Max Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M. Abate, M. Bassendine, U. Spengler, G. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Müller, M. Bahlo, G. Stewart, D. Booth, J. George (2009)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapyNature Genetics, 41
H. Abe, H. Ochi, T. Maekawa, C. Hayes, M. Tsuge, D. Miki, Fukiko Mitsui, N. Hiraga, M. Imamura, Shoichi Takahashi, W. Ohishi, W. Ohishi, K. Arihiro, M. Kubo, Yusuke Nakamura, K. Chayama (2010)
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.Journal of hepatology, 53 3
J. Hoofnagle, M. Ghany, D. Kleiner, E. Doo, T. Heller, K. Promrat, J. Ong, Farooq Khokhar, A. Soza, D. Herion, Y. Park, J. Everhart, T. Liang (2003)
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirinHepatology, 38
M. Naito, A. Matsui, M. Inao, S. Nagoshi, M. Nagano, Nobuko Ito, T. Egashira, M. Hashimoto, S. Mishiro, S. Mochida, K. Fujiwara (2005)
SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis CJournal of Gastroenterology, 40
N. Akuta, F. Suzuki, M. Hirakawa, Y. Kawamura, Hiromi Yatsuji, H. Sezaki, Yoshiyuki Suzuki, T. Hosaka, M. Kobayashi, M. Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, K. Chayama, Yusuke Nakamura, H. Kumada (2010)
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirinHepatology, 52
N. Matsuyama, S. Mishiro, M. Sugimoto, Y. Furuichi, M. Hashimoto, M. Hijikata, Y. Ohta (2003)
The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon.Hepatology research : the official journal of the Japan Society of Hepatology, 25 3
N. Akuta, F. Suzuki, H. Sezaki, Yoshiyuki Suzuki, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, S. Watahiki, J. Sato, M. Matsuda, M. Kobayashi, Y. Arase, K. Ikeda, H. Kumada (2005)
Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination TherapyIntervirology, 48
K. Kiyosawa, T. Sodeyama, E. Tanaka, Y. Gibo, K. Yoshizawa, Y. Nakano, S. Furuta, Y. Akahane, K. Nishioka, R. Purcell, H. Alter (1990)
Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virusHepatology, 12
A. Lonardo, L. Adinolfi, P. Loria, N. Carulli, G. Ruggiero, C. Day (2004)
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease.Gastroenterology, 126 2
Y. Ohnishi, Toshihiro Tanaka, K. Ozaki, R. Yamada, Hideyuki Suzuki, Yusuke Nakamura (2001)
A high-throughput SNP typing system for genome-wide association studiesJournal of Human Genetics, 46
M. Hijikata, Y. Ohta, S. Mishiro (2000)
Identification of a Single Nucleotide Polymorphism in the MxA Gene Promoter (G/T at nt –88) Correlated with the Response of Hepatitis C Patients to InterferonIntervirology, 43
K. Chayama, A. Tsubota, M. Kobayashi, K. Okamoto, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, Yoshiyuki Suzuki, N. Murashima, K. Ikeda, H. Kumada (1997)
Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infectionHepatology, 25
T. Vanwolleghem, L. Libbrecht, B. Hansen, I. Desombere, T. Roskams, P. Meuleman, G. Leroux-Roels (2010)
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice.Journal of hepatology, 53 3
J. McHutchison, S. Gordon, E. Schiff, M. Shiffman, William Lee, V. Rustgi, Z. Goodman, M. Ling, S. Cort, J. Albrecht (1998)
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.The New England journal of medicine, 339 21
Manns (2001)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet, 358
F. Eng, J. Walewski, Arielle Klepper, S. Fishman, S. Desai, L. McMullan, M. Evans, C. Rice, A. Branch (2009)
Internal Initiation Stimulates Production of p8 Minicore, a Member of a Newly Discovered Family of Hepatitis C Virus Core Protein IsoformsJournal of Virology, 83
D. Ge, J. Fellay, A. Thompson, J. Simon, K. Shianna, T. Urban, E. Heinzen, P. Qiu, A. Bertelsen, A. Muir, M. Sulkowski, J. McHutchison, D. Goldstein (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 461
D. Mercer, D. Schiller, J. Elliott, D. Douglas, C. Hao, A. Rinfret, W. Addison, K. Fischer, T. Churchill, J. Lakey, D. Tyrrell, N. Kneteman (2001)
Hepatitis C virus replication in mice with chimeric human liversNature Medicine, 7
M. Fried, M. Shiffman, R. Sterling, J. Weinstein, J. Crippin, G. Garcia, T. Wright, H. Conjeevaram, R. Reddy, J. Peter, G. Cotsonis, F. Nolte (2000)
A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotypeAmerican Journal of Gastroenterology, 95
Michael Fried, Mitchell Shiffman, K. Reddy, Coleman Smith, George Marinos, F. Gonçales, Dieter Häussinger, Moisés Diago, Giampiero Carosi, Daniel Dhumeaux, A. Craxì, A. Lin, Joseph Hoffman, Jian Yu (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.The New England journal of medicine, 347 13
Takashi Kimura, M. Imamura, N. Hiraga, Tsuyoshi Hatakeyama, D. Miki, Chiemi Noguchi, N. Mori, M. Tsuge, Shoichi Takahashi, Y. Fujimoto, E. Iwao, H. Ochi, H. Abe, T. Maekawa, K. Arataki, C. Tateno, K. Yoshizato, T. Wakita, T. Okamoto, Y. Matsuura, K. Chayama (2008)
Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice.The Journal of general virology, 89 Pt 9
M. Sarasin-Filipowicz, E. Oakeley, F. Duong, V. Christen, L. Terracciano, W. Filipowicz, M. Heim (2008)
Interferon signaling and treatment outcome in chronic hepatitis CProceedings of the National Academy of Sciences, 105
N. Kneteman, A. Weiner, J. O’Connell, M. Collett, Tiejun Gao, L. Aukerman, Rosemary Kovelsky, Z. Ni, Ahmad Hashash, Janine Kline, B. Hsi, D. Schiller, D. Douglas, D. Tyrrell, D. Mercer (2006)
Anti‐HCV therapies in chimeric scid‐Alb/uPA mice parallel outcomes in human clinical applicationHepatology, 43
(2009)
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
N. Mori, M. Imamura, Y. Kawakami, Hiromi Saneto, T. Kawaoka, S. Takaki, H. Aikata, Shoichi Takahashi, K. Chayama (2009)
Randomized trial of high‐dose interferon‐α‐2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapyJournal of Medical Virology, 81
A. Suzuki, R. Yamada, X. Chang, S. Tokuhiro, T. Sawada, Masakatsu Suzuki, Miyuki Nagasaki, Makiko Nakayama-Hamada, R. Kawaida, Mitsuru Ono, M. Ohtsuki, H. Furukawa, S. Yoshino, M. Yukioka, S. Tohma, T. Matsubara, S. Wakitani, R. Teshima, Y. Nishioka, A. Sekine, A. Iida, A. Takahashi, T. Tsunoda, Yusuke Nakamura, K. Yamamoto (2003)
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritisNature Genetics, 34
C. Tateno, Y. Yoshizane, N. Saito, M. Kataoka, R. Utoh, C. Yamasaki, Asato Tachibana, Y. Soeno, K. Asahina, H. Hino, T. Asahara, T. Yokoi, T. Furukawa, K. Yoshizato (2004)
Near completely humanized liver in mice shows human-type metabolic responses to drugs.The American journal of pathology, 165 3
Y. Ohnishi (2002)
[A high-throughput SNP typing system for genome-wide association studies].Gan to kagaku ryoho. Cancer & chemotherapy, 29 11
C. Niederau, Stefan Lange, T. Heintges, A. Erhardt, Marlies Buschkamp, D. Hürter, M. Nawrocki, L. Kruska, F. Hensel, W. Petry, D. Häussinger (1998)
Prognosis of chronic hepatitis c: Results of a large, prospective cohort studyHepatology, 28
N. Kamiya, E. Iwao, N. Hiraga, M. Tsuge, M. Imamura, Shoichi Takahashi, Shinji Miyoshi, C. Tateno, K. Yoshizato, K. Chayama (2010)
Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.The Journal of general virology, 91 Pt 7
C. Hayes, M. Kobayashi, N. Akuta, F. Suzuki, H. Kumada, H. Abe, D. Miki, M. Imamura, H. Ochi, N. Kamatani, Yusuke Nakamura, K. Chayama (2010)
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapyGut, 60
T. Poynard, V. Ratziu, J. McHutchison, M. Manns, Z. Goodman, S. Zeuzem, Z. Younossi, J. Albrecht (2003)
Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis CHepatology, 38
C. Rui (2012)
Genetic variation in IL-28B and spontaneous clearance of hepatitis C virusJournal of Capital Medical University
T. Welzel, T. Morgan, H. Bonkovsky, D. Naishadham, R. Pfeiffer, E. Wright, A. Hutchinson, A. Crenshaw, A. Bashirova, M. Carrington, M. Dotrang, R. Sterling, K. Lindsay, R. Fontana, William Lee, A. Bisceglie, M. Ghany, D. Gretch, S. Chanock, R. Chung, T. O'Brien (2009)
Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trialHepatology, 49
N. Akuta, F. Suzuki, Y. Kawamura, Hiromi Yatsuji, H. Sezaki, Yoshiyuki Suzuki, T. Hosaka, M. Kobayashi, M. Kobayashi, Y. Arase, K. Ikeda, H. Kumada (2007)
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.Journal of hepatology, 46 3
N. Akuta, F. Suzuki, M. Hirakawa, Y. Kawamura, Hiromi Yatsuji, H. Sezaki, Yoshiyuki Suzuki, T. Hosaka, M. Kobayashi, M. Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, H. Kumada (2009)
A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological responseJournal of Medical Virology, 81
N. Hiraga, M. Imamura, M. Tsuge, Chiemi Noguchi, Shoichi Takahashi, E. Iwao, Y. Fujimoto, H. Abe, T. Maekawa, H. Ochi, C. Tateno, K. Yoshizato, A. Sakai, Y. Sakai, M. Honda, S. Kaneko, T. Wakita, K. Chayama (2007)
Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferonFEBS Letters, 581
T. Okanoue, Y. Itoh, Hiroaki Hashimoto, K. Yasui, M. Minami, T. Takehara, E. Tanaka, M. Onji, J. Toyota, K. Chayama, K. Yoshioka, N. Izumi, N. Akuta, H. Kumada (2009)
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center studyJournal of Gastroenterology, 44
S. Knapp, L. Yee, L. Yee, A. Frodsham, B. Hennig, S. Hellier, Lyna Zhang, M. Wright, M. Chiaramonte, M. Graves, H. Thomas, A. Hill, M. Thursz (2003)
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKRGenes and Immunity, 4
M. Montes-Cano, J. García-Lozano, C. Abad-Molina, M. Romero‐Gomez, N. Barroso, J. Aguilar‐Reina, A. Nunez‐roldan, M. González-Escribano (2010)
Interleukin‐28B genetic variants and hepatitis virus infection by different viral genotypesHepatology, 52
For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group
Amino acid (aa) substitutions of core 70 and 91 and in the NS5A (nonstructural protein 5A) interferon sensitivity determining region (ISDR) as well as genetic polymorphisms in the host interleukin‐28B (IL28B) locus affect the outcome of interferon (IFN)‐based therapies for patients with chronic hepatitis C. The combination of these factors and the quasispecies nature of the virus complicate understanding of the underlying mechanism. Using infectious hepatitis C virus (HCV) genotype 1b clone HCV‐KT9, we introduced substitutions at both core aa70 (Arg to Gln) and aa91 (Leu to Met). We also introduced four and nine ISDR aa substitutions into core mutant HCV‐KT9. Using human hepatocyte chimeric mice with different IL28B genotypes, we examined the infectivity, replication ability, and susceptibility to IFN of these clones. Although aa substitutions in the ISDR significantly impaired infectivity and replication ability of the virus, core aa70 and 91 substitutions did not. The effect of IFN treatment was similar in core wild‐type and mutant viruses. Interestingly, virus titer was significantly higher in mice with the favorable IL28B allele (rs8099917 TT and rs12979860 CC) in the transplanted hepatocytes than in mice with hepatocytes from rs8099917 TG and rs12979860 TT donors (P < 0.001). However, the effect of IFN was significantly greater, and intrahepatic expression levels of IFN‐stimulated genes were significantly higher in mice with the favorable IL28B allele. Conclusion: Our data suggest that HCV replication levels and response to IFN are affected by human hepatocyte IL28B single‐nucleotide polymorphism genotype and mutations in the ISDR. The mechanism underlying the clinically observed association of wild‐type core protein in eradication‐favorable host cells should be investigated further. (HEPATOLOGY 2011;)
Hepatology – Wiley
Published: Sep 2, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.